The expansion forms part of Lilly’s broader $50bn capital investment programme to grow its US manufacturing and production ...

Eli Lilly and Company has announced plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Puerto Rico.

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

Guardant Health, Inc. shows strong adoption and revenue growth in oncology and data. Click for my updated look at GH stock ...

Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most ...

The stock market had strong weekly gains after huge earnings, the latest Federal Reserve move and a Trump-Xi meeting.